Last reviewed · How we verify
UCB4940 560 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
UCB4940 560 mg (UCB4940 560 mg) — UCB Celltech.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| UCB4940 560 mg TARGET | UCB4940 560 mg | UCB Celltech | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- UCB4940 560 mg CI watch — RSS
- UCB4940 560 mg CI watch — Atom
- UCB4940 560 mg CI watch — JSON
- UCB4940 560 mg alone — RSS
Cite this brief
Drug Landscape (2026). UCB4940 560 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/ucb4940-560-mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing